Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methyldopa→

Methyldopa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
555-30-6
Molecular formula
C10H13NO4
Molecular weight
211.21 g/mol
Drug class
Centrally acting alpha-2 adrenergic agonistantihypertensive
Mechanism of action
Converted in the central nervous system to alpha-methylnorepinephrine, which stimulates central inhibitory alpha-2 adrenergic receptors and reduces sympathetic outflow, peripheral vascular resistance and blood pressure.
Indications / reported uses
  • Treatment of hypertension in adults; methyldopa has a long history of use in pregnancy-related hypertension in some jurisdictions, but choice of treatment should follow current obstetric and national guidance

Sources: US DailyMed — Methyldopa tablets · NLM MeSH — Methyldopa · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methyldopa Environmental Risk Assessment (ERA) (the Methyldopa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.